ReviewHuman vaccines & immunotherapeutics2017
Immune persistence after pertussis vaccination.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 68 citations in OpenAlex.
- Epidemiological characteristics and vaccination history analysis of pertussis in Quzhou from 2005 to 2024.Journal of health, population, and nutrition · 2026Article
- Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults.Vaccines · 2026Article
- Analysis of Macrolide Resistance inBiomedicines · 2026Article
- Specific IgG levels before and one month after administration of a booster dose of the diphtheria, tetanus, and pertussis vaccine in 14-year-old adolescents.Frontiers in immunology · 2026Article
- Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance.Human vaccines & immunotherapeutics · 2025Review
- Pertussis-A Re-Emerging Threat Despite Immunization: An Analysis of Vaccine Effectiveness and Antibiotic Resistance.International journal of molecular sciences · 2025Review
- Resurgence of pertussis: whopping the '100-day cough'.Current opinion in pediatrics · 2025Review
- Seroepidemiological Assessment ofHealth care science · 2025Article
- Antibody persistence to diphtheria toxoid, tetanus toxoid,Human vaccines & immunotherapeutics · 2024Article
- Public health management of pertussis in adults: Practical challenges and future strategies.Human vaccines & immunotherapeutics · 2024Review
- Comparison Between Simple Batch and Fed-Batch Bioreactor Cultivation of Recombinant BCG.Pharmaceutics · 2024Article
- Article
- BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infection and immunity · 2024Article
- Serological responses to immunization during nephrosis in infants with congenital nephrotic syndrome of the Finnish type.Frontiers in pediatrics · 2024Article
- T cell reactivity to Bordetella pertussis is highly diverse regardless of childhood vaccination.Cell host & microbe · 2023Article
- A Sensitive Public Health Issue-The Vaccine Acceptancy and the Anti-Pertussis Immune Status of Pregnant Women from a Romanian Metropolitan Area.Children (Basel, Switzerland) · 2023Article
- Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity.Vaccines · 2022Review
- Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination.Nature communications · 2022Article
- Hand disinfectants and their activity against clinical isolates of Bordetella pertussis.Central European journal of public health · 2022Article
- Descriptive Overview of Pertussis Epidemiology Among Older Adults in Europe During 2010-2020.Infectious diseases and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis is one of the most prevalent vaccine-preventable diseases worldwide. The true infection rate is significantly higher than the reported incidence rate. An increased prevalence of pertussis in older populations has been found, mainly caused by waning immunity after vaccination. Vaccine-induced immunity differs due to variation in vaccine content, schedule and coverage. Protection following acellular pertussis vaccines has been suggested to wane faster than whole cell pertussis vaccines. However, long-term immune persistence of whole cell pertussis vaccines may be confounded by a progressive acquisition of natural immunity. The World Health Organization has recommended that a switch from whole cell to acellular pertussis vaccines for primary immunization in infants should only be considered if additional periodic boosters or maternal immunization can be ensured and sustained in the national immunization schedules. In this review, we present data on immune persistence after different pertussis vaccinations and compare the findings from countries with different vaccination strategies. Future aspects in serological studies are briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.